UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 206

Sortiert nach

Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre‐exposure prophylaxis

HIV medicine, 2017-07, Vol.18 (6), p.412-418

2017

Volltextzugriff (PDF)

High IP‐10 levels decrease T cell function in HIV‐1‐infected individuals on ART

Journal of leukocyte biology, 2014-12, Vol.96 (6), p.1055-1063

2014

Volltextzugriff (PDF)

Effect of Statin Therapy in Reducing the Risk of Serious Non-AIDS-Defining Events and Nonaccidental Death

Clinical infectious diseases, 2013-05, Vol.56 (10), p.1471-1479

2013

Volltextzugriff (PDF)

PP 8.10 – 00155 Evaluation of HIV-specific T cell response in BEAT2 clinical trial

Journal of Virus Eradication, 2022-12, Vol.8, p.100290, Article 100290

2022

Volltextzugriff (PDF)

Current Concepts in the Diagnosis and Management of Metabolic Complications of HIV Infection and Its Therapy

Clinical infectious diseases, 2006-09, Vol.43 (5), p.645-653

2006

Volltextzugriff (PDF)

Prospects for cure of HIV

International journal of infectious diseases, 2018-08, Vol.73, p.40-40

Tebas, P.

2018

Volltextzugriff (PDF)

Effects of Potent Antiretroviral Therapy on Free Testosterone Levels and Fat-Free Mass in Men in a Prospective, Randomized Trial: A5005s, a Substudy of AIDS Clinical Trials Group Study 384

Clinical infectious diseases, 2007-07, Vol.45 (1), p.120-126

2007

Volltextzugriff (PDF)

PP 7.2 – 00006 Acceptability of Home-Based Blood Collection Device for Viral Load Testing in HIV Cure Trials with Analytical Treatment Interruptions

Journal of Virus Eradication, 2022-12, Vol.8, p.100264, Article 100264

2022

Volltextzugriff (PDF)

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

AIDS (London), 2012-04, Vol.26 (7), p.825-831

2012

Volltextzugriff (PDF)

Distinct HIV reservoir measures correlate with defective but not intact pro-viral DNA

Journal of Virus Eradication, 2019-12, Vol.5, p.7

2019

Volltextzugriff (PDF)

Cleaving HIV-1 provirus from ART-suppressed patient-derived resting CD4 T Cells using Cpf1/crRNA-array ribonucleotide protein packaged by CD4-targeting lentivirus-like particle

Journal of Virus Eradication, 2019-12, Vol.5, p.55-56

2019

Volltextzugriff (PDF)

Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110

Journal of antimicrobial chemotherapy, 2009-05, Vol.63 (5), p.998-1005

2009

Volltextzugriff (PDF)

Baseline inducible HIV P24 is associated with viral control during interferon-α monotherapy with ART interruption

Journal of Virus Eradication, 2019-12, Vol.5, p.32-33

2019

Volltextzugriff (PDF)

Niacin in HIV-Infected Individuals with Hyperlipidemia Receiving Potent Antiretroviral Therapy

Clinical infectious diseases, 2004-08, Vol.39 (3), p.419-425

2004

Volltextzugriff (PDF)

Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers

Clinical infectious diseases, 2010-10, Vol.51 (8), p.937-946

2010

Volltextzugriff (PDF)

Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy

Journal of applied physiology (1985), 2001-01, Vol.90 (1), p.133-138

2001

Volltextzugriff (PDF)

Brief ATI does not alter the size or composition of the latent HIV-1 reservoir

Journal of Virus Eradication, 2017-12, Vol.3, p.40-41

2017

Volltextzugriff (PDF)

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

The Lancet (British edition), 2014-06, Vol.383 (9936), p.2222-2231

2014

Volltextzugriff (PDF)

Abacavir Use and Risk of Acute Myocardial Infarction and Cerebrovascular Events in the Highly Active Antiretroviral Therapy Era

Clinical infectious diseases, 2011-07, Vol.53 (1), p.84-91

2011

Volltextzugriff (PDF)

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

The Journal of infectious diseases, 2014-08, Vol.210 (3), p.354-362

2014

Volltextzugriff (PDF)

Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals

AIDS (London), 2010-09, Vol.24 (14), p.2187-2192

2010

Volltextzugriff (PDF)

CD32+ CD4+ T Cells are HIV transcriptionally active rather than a resting reservoir

Journal of Virus Eradication, 2017-12, Vol.3, p.9

2017

Volltextzugriff (PDF)

Bone Disease and HIV Infection

Clinical infectious diseases, 2006-01, Vol.42 (1), p.108-114

2006

Volltextzugriff (PDF)

Low Baseline CD4+Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation

Clinical infectious diseases, 2013-11, Vol.57 (10), p.1483-1488

2013

Volltextzugriff (PDF)

Potent cellular immune responses after therapeutic immunization of HIV-positive patients with the PENNVAX®-B DNA vaccine in a Phase I Trial

Retrovirology, 2012-09, Vol.9 (S2), p.P276-P276, Article P276

2012

Volltextzugriff (PDF)

1 – 25 von 206

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(197)
Mit Volltextzugriff
(174)

Publikationsform

Artikel
(204)
Berichte
(2)

Sprache

Englisch
(198)
Japanisch
(19)
Spanisch
(8)

Erscheinungsjahr

n.n

Thema

Humans
(155)
Science & Technology
(146)
Life Sciences & Biomedicine
(145)
Male
(116)
Female
(109)
Infectious Diseases
(108)
Adult
(102)
Hiv Infections - Drug Therapy
(88)
Biological And Medical Sciences
(85)
Immunology
(84)
Medical Sciences
(84)
Middle Aged
(79)
Human Immunodeficiency Virus
(77)
Hiv
(67)
Microbiology
(60)
Human Viral Diseases
(58)
Viral Diseases
(58)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(52)
Virology
(51)
Anti-Hiv Agents - Therapeutic Use
(49)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre‐exposure prophylaxis

High IP‐10 levels decrease T cell function in HIV‐1‐infected individuals on ART

Effect of Statin Therapy in Reducing the Risk of Serious Non-AIDS-Defining Events and Nonaccidental Death

PP 8.10 – 00155 Evaluation of HIV-specific T cell response in BEAT2 clinical trial

Current Concepts in the Diagnosis and Management of Metabolic Complications of HIV Infection and Its Therapy

Prospects for cure of HIV

Effects of Potent Antiretroviral Therapy on Free Testosterone Levels and Fat-Free Mass in Men in a Prospective, Randomized Trial: A5005s, a Substudy of AIDS Clinical Trials Group Study 384

PP 7.2 – 00006 Acceptability of Home-Based Blood Collection Device for Viral Load Testing in HIV Cure Trials with Analytical Treatment Interruptions

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

Distinct HIV reservoir measures correlate with defective but not intact pro-viral DNA

Cleaving HIV-1 provirus from ART-suppressed patient-derived resting CD4 T Cells using Cpf1/crRNA-array ribonucleotide protein packaged by CD4-targeting lentivirus-like particle

Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110

Baseline inducible HIV P24 is associated with viral control during interferon-α monotherapy with ART interruption

Niacin in HIV-Infected Individuals with Hyperlipidemia Receiving Potent Antiretroviral Therapy

Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers

Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy

Brief ATI does not alter the size or composition of the latent HIV-1 reservoir

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Abacavir Use and Risk of Acute Myocardial Infarction and Cerebrovascular Events in the Highly Active Antiretroviral Therapy Era

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals

CD32+ CD4+ T Cells are HIV transcriptionally active rather than a resting reservoir

Bone Disease and HIV Infection

Low Baseline CD4+Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation

Potent cellular immune responses after therapeutic immunization of HIV-positive patients with the PENNVAX®-B DNA vaccine in a Phase I Trial

Suchergebnisse filtern